Patience Is A Virtue For French VC Kurma
Executive Summary
Thierry Laugel, managing partner of the Paris-based financiers, tells Scrip about the virtues of its 'company creation model,' giving innovative ideas time to mature rather than rushing to the market.
You may also be interested in...
Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact
BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.
Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.
ImCheck Therapeutics Pursues Immuno-Oncology Antibodies
Emerging Company Profile: The new anticancer antibody developer ImCheck Therapeutics has set up in Marseille, France, a location that is becoming increasingly attractive to biotech start-ups that could rival more established areas in coming years.
Need a specific report? 1000+ reports available
Buy Reports